Stefan Oelrich, a member of the management board of Bayer AG and President Bayer Pharmaceuticals: We look at the level of Europe, as an industry, to be more independent of imports, especially when it comes to active substances.
♦ Stefan Oelrich, a member of the management board of Bayer AG and President Bayer Pharmaceuticals: «The free exchange of goods helped us to prosper worldwide. Our company supports free exchange. Medications have been excluded from sanctions and various rules and it is strange that now we speak of tariffs for drugs» ♦ had sales of 46.6 billion euros at group level and over 90,000 employees.
The challenges in the pharma industry are both older ones – different and heavy access to new drugs, price differences that lead to parallel exports, but new ones, such as commercial rates that the new administration in the United States wants to impose. In this context, in the field of drugs, more independence is needed compared to imports of active substances at the level of the European Union, says Stefan Oelich, a member of the management board of Bayer AG and President Bayer Pharmaceuticals. He participated in Berlin in the Bayer Pharma Media Day 2025 event, who brought together representatives of Bayer and journalists from several parts of the world, where the company has presence. «We look at the level of Europe, as an industry, to be more independent of imports, especially when it comes to active substances. However, globalization is not guilty for discontinuities in the supply chains. In all 27 states of the European Union we have different drug access schemes.
For other news, analyzes, articles and information from real -time business follows the financial newspaper on WhatsApp Channels